Titlebook: Genome Editing in Cardiovascular and Metabolic Diseases; Junjie Xiao Book 2023 The Editor(s) (if applicable) and The Author(s), under excl

平庸的人或物

Genome Editing in Dyslipidemia and Atherosclerosissafety issues related to the once-and-done therapy focusing on CRISPR/Cas systems. We give an outlook on the potential gene targets prioritized by large-scale genetic studies of cardiovascular diseases and genome editing in precision medicine of dyslipidemia and atherosclerosis.

hurricane

Genomic Editing and Diabetesays involved in development of diabetes and its complications. Consequently, developing further understanding of genetics and its messenger pathways in diabetes would enhance our ability to develop precise and accurate genetic editing tools which can translate into clinically useful therapeutics.

BRIBE

CREST

lymphedema

https://doi.org/10.1007/978-3-030-74184-6present the existing knowledge of genetic analysis and genome editing for atrial fibrillation, indicating the existing gaps and future directions. We aim to elucidate how genome editing could be utilized for patients with atrial fibrillation.

極大痛苦

DEFT

Genome Editing and Cardiac Regenerationitations associated with in vitro and in vivo aspects of cardiac regeneration, such as imaging and immune rejection. In this chapter, the pathways involved in cardiac regeneration will be highlighted, and the role of gene-editing tools in endogenous and exogenous approaches to regenerate injured myocardium is discussed.

健談

Genome Editing and Atrial Fibrillationpresent the existing knowledge of genetic analysis and genome editing for atrial fibrillation, indicating the existing gaps and future directions. We aim to elucidate how genome editing could be utilized for patients with atrial fibrillation.

易于

Genome Editing to Abrogate Muscle Atrophyging field of genome editing is gaining momentum as it has shown great advantage in the treatment of various diseases, including muscle atrophy. In our current review, we systematically evaluate the etiology and related signaling pathways of muscle atrophy and discuss the application of genome editing in the treatment of muscle atrophy.

難管

An Overview of Genome Editing in Cardiovascular and Metabolic Diseasescular and metabolic diseases for disease modeling, diagnostics, and therapeutics, with a particular focus on clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated 9 (Cas9) technology as applied to nuclease editing, base editing, and epigenome editing.